TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24631451

Group type: EXPERIMENTAL
Intervention: Persistent high-risk (hr) HPV infection in women with primary CIN3+ and recurrent CIN2+
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Primary HPV16- and HPV18-infected CIN3+
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: HPV33-infected CIN3+
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Other HPV type-infected CIN3+
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Routine post-conization hr-HPV DNA testing and cervical cytology
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Adolescent vaccination
Number of subjects: 58
Study: 24631511

Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with plaque rupture
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Patients with subclinical, nonculprit plaque ruptures
Number of subjects: 660
Study: 24631512

Group type: EXPERIMENTAL
Intervention: Resting myocardial tissue Doppler velocities (s', a', e')
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Resting eas index
Number of subjects: 225

Group type: COMPARATOR
Intervention: Exercise stress testing
Number of subjects: 225
Study: 24632880

Group type: EXPERIMENTAL
Intervention: Placebo surgery
Number of subjects: 100
Study: 24633206

Group type: EXPERIMENTAL
Intervention: Tigecycline therapy for ≥1 month (mean, 255.0 ± 265.7 days)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tigecycline therapy for ≥1 month (mean, 143 ± 123 days)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tigecycline therapy
Number of subjects: 52
Study: 24633881

Group type: EXPERIMENTAL
Intervention: Subclinical atrial fibrillation (SCAF) >6 minutes in duration
Number of subjects: 2580

Group type: EXPERIMENTAL
Intervention: SCAF detected before stroke or systemic embolism
Number of subjects: 2580

Group type: EXPERIMENTAL
Intervention: SCAF detected within 30 days before stroke or systemic embolism
Number of subjects: 2580

Group type: EXPERIMENTAL
Intervention: SCAF detected >30 days before stroke or systemic embolism
Number of subjects: 2580

Group type: EXPERIMENTAL
Intervention: SCAF detected only after stroke
Number of subjects: 2580
Study: 24634371

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2458
Study: 24634374

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes with DC vaccination (n = 10)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes without DC vaccination (n = 3)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Freshly manufactured TCR transgenic T cells
Number of subjects: 14
Study: 24635447

Group type: EXPERIMENTAL
Intervention: Prolotherapy with hypertonic dextrose and morrhuate sodium injections (15% dextrose and 5% morrhuate sodium) at peri-articular tendon and ligament insertions, and a single intra-articular injection of 6 mL 25% dextrose.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Prolotherapy with hypertonic dextrose and morrhuate sodium injections.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Postprocedure opioid medication use.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Participant satisfaction after prolotherapy injections.
Number of subjects: 38
Study: 24636025

Group type: EXPERIMENTAL
Intervention: ADHD with deficits in both SWM and SOC tasks (n=121)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: ADHD with deficit in either SWM or SOC task (n=185)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: ADHD without deficits in SWM or SOC task (n=205)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Non-ADHD controls (n=124)
Number of subjects: 511
Study: 24636429

Group type: EXPERIMENTAL
Intervention: Doripenem (500mg intravenously, infused over 1h or 4h every 8h for 5-14 days)
Number of subjects: 216
Study: 24637635

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg) administered before tumor resection
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bevacizumab pharmacokinetics
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Body mass index percentile
Number of subjects: 27
Study: 24637689

Group type: EXPERIMENTAL
Intervention: Danoprevir and mericitabine combination treatment
Number of subjects: 89
Study: 24638012

Group type: EXPERIMENTAL
Intervention: Rituximab plus chlorambucil (R-chlorambucil)
Number of subjects: 100
Study: 24638072

Group type: EXPERIMENTAL
Intervention: Moderately intensive chemotherapy for HIV-1 related lymphoma
Number of subjects: 9
Study: 24639271

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (10^8 colony-forming units, n = 168)
Number of subjects: 336
Study: 24639720

Group type: EXPERIMENTAL
Intervention: Pentoxifylline used for semen processing (group I)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pentoxifylline used for semen processing (group IIIA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No pentoxifylline used for semen processing (group II)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No pentoxifylline used for semen processing (group IIIB)
Number of subjects: 120
Study: 24641955

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents (cyclophosphamide, glucocorticosteroids, mycophenolate mofetil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Renin-angiotensin blockade
Number of subjects: 0
Study: 24642016

Group type: EXPERIMENTAL
Intervention: Intrathecal delivery of autologous bone marrow-derived total nucleated cells (TNC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous injection of autologous bone marrow-derived total nucleated cells (TNC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MRI assessment at 6 months post-therapy
Number of subjects: 18
Study: 24642140

Group type: EXPERIMENTAL
Intervention: Healthy Directions 2 (HD2)
Number of subjects: 2440

Group type: EXPERIMENTAL
Intervention: Healthy Directions 2 plus 2 brief telephone coaching calls (HD2+CC)
Number of subjects: 2440

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 2440
Study: 24642247

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1.8 mg/kg intravenously approximately every 3 weeks over 30 minutes
Number of subjects: 29
Study: 24642467

Group type: EXPERIMENTAL
Intervention: Periodic repolarization dynamics (PRD)
Number of subjects: 2965

Group type: COMPARATOR
Intervention: Pharmacological blockade of sympathetic nervous system activity
Number of subjects: 2965
Study: 24642999

Group type: EXPERIMENTAL
Intervention: Routine measurement of fractional flow reserve (FFR) during coronary angiography (CA)
Number of subjects: 200
Study: 24643408

Group type: EXPERIMENTAL
Intervention: Common carotid artery interadventitial diameter
Number of subjects: 6255

Group type: EXPERIMENTAL
Intervention: Common carotid artery interadventitial diameter after adjustment for risk factors and common carotid IMT
Number of subjects: 6255

Group type: EXPERIMENTAL
Intervention: Common carotid IMT
Number of subjects: 6255
Study: 24643601

Group type: EXPERIMENTAL
Intervention: Age-adjusted D-dimer cutoff (age × 10)
Number of subjects: 3346

Group type: COMPARATOR
Intervention: Fixed D-dimer cutoff of 500 µg/L
Number of subjects: 3346
Study: 24643960

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (rIPC) with circulating nitrite
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pharmacological and genetic inhibition of nitric oxide/nitrite generation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transfer of plasma from healthy volunteers subjected to rIPC
Number of subjects: 100
Study: 24643964

Group type: EXPERIMENTAL
Intervention: Self-generated highly positive script
Number of subjects: 105
Study: 24644022

Group type: EXPERIMENTAL
Intervention: Modular IFN signature analysis in SLE patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Moderate/strong modular scores (2 or 3 active IFN modules)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of modular IFN signature
Number of subjects: 62
Study: 24646009

Group type: EXPERIMENTAL
Intervention: HI serology
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Plasma levels of IL-6 and IL-10
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: H1N1-specific T-cell responses
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: B-cell immunophenotyping and plasma levels of immunoglobulin classes
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ELISA and microneutralization titers
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 222G hemagglutinin mutation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Influenza A(H1N1) 2009 viremia
Number of subjects: 34
Study: 24646518

Group type: EXPERIMENTAL
Intervention: Oral 300,000 units cholecalciferol administered at baseline and 8-weeks
Number of subjects: 26
Study: 24646562

Group type: EXPERIMENTAL
Intervention: Hepatic-arterial infusion plus systemic chemotherapy including bevacizumab (Bev)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hepatic-arterial infusion plus systemic chemotherapy without bevacizumab (Bev)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Resected patients
Number of subjects: 49
Study: 24647146

Group type: EXPERIMENTAL
Intervention: Positive QFT-TB results
Number of subjects: 391

Group type: COMPARATOR
Intervention: Negative or indeterminate QFT-TB results
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: TST and QFT-TB
Number of subjects: 391

Group type: COMPARATOR
Intervention: Positive TST
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Negative TST with positive QFT-TB
Number of subjects: 391

Group type: COMPARATOR
Intervention: Negative TST with negative or indeterminate QFT-TB
Number of subjects: 391
Study: 24647218

Group type: EXPERIMENTAL
Intervention: Adult ADHD Symptoms Self-Report (ASRS)
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Potential correlates of ADHD symptoms in relatives
Number of subjects: 1171
Study: 24647275

Group type: EXPERIMENTAL
Intervention: Postmortem cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 359
Study: 24647376

Group type: EXPERIMENTAL
Intervention: Viscum album mother tincture (10 drops, 3 times a day for 12 weeks)
Number of subjects: 0
Study: 24647390

Group type: EXPERIMENTAL
Intervention: Plasma vitamin B-6 (pyridoxal-5'-phosphate)
Number of subjects: 1976

Group type: EXPERIMENTAL
Intervention: Homocysteine (μmol/L)
Number of subjects: 1976

Group type: EXPERIMENTAL
Intervention: Plasma PLP, RBC folate, homocysteine, and cysteine
Number of subjects: 1976

Group type: EXPERIMENTAL
Intervention: PLP, vitamin B-12, RBC folate, and homocysteine
Number of subjects: 1976

Group type: EXPERIMENTAL
Intervention: Stratification by folic acid fortification period
Number of subjects: 1976
Study: 24647408

Group type: EXPERIMENTAL
Intervention: ATS guidelines for predicting infection or colonization with MDROs at ICU admission
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: ATS guidelines for predicting infection or colonization with MDROs at ICU discharge
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: ATS guidelines in departments with MDRO infection rates of 31-40%
Number of subjects: 610
Study: 24647802

Group type: EXPERIMENTAL
Intervention: Isolated insular strokes
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: MR-proANP levels
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression models including stroke location and MR-proANP levels
Number of subjects: 104
Study: 24647849

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (matched diabetic patients)
Number of subjects: 20
Study: 24649361

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 75 µg with bupivacaine (group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 0.5 mL with bupivacaine (group F)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intrathecal distilled water 0.5 mL with bupivacaine (group P)
Number of subjects: 90
Study: 24649373

Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration (FNA)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Core Biopsy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Comparison of FNA and Core Biopsy
Number of subjects: 105
Study: 24649919

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 2 weeks
Number of subjects: 14
Study: 24650638

Group type: EXPERIMENTAL
Intervention: Shoulder physical activity (SPA) assessed by RT3 accelerometers
Number of subjects: 26

Group type: COMPARATOR
Intervention: Improvement group
Number of subjects: 26
Study: 24650809

Group type: EXPERIMENTAL
Intervention: Microdecompression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laminectomy
Number of subjects: 0
Study: 24651258

Group type: COMPARATOR
Intervention: Pseudoxanthoma elasticum patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 75
Study: 24651570

Group type: EXPERIMENTAL
Intervention: DWI-FLAIR mismatch
Number of subjects: 56
Study: 24651704

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 24652353

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (55%-75% maximum heart rate for 60 min, three times a week for 12 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual physical activity (control group)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 35
Study: 24652992

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1.8 mg/kg administered every 3 weeks until progression or unacceptable toxicity
Number of subjects: 35
Study: 24652994

Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab-tiuxetan (Zevalin)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Historic control from MCL2 trial
Number of subjects: 160
Study: 24653510

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/d) + Atorvastatin (10 mg/d)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Rosuvastatin (2.5 mg/d)
Number of subjects: 125
Study: 24653513

Group type: EXPERIMENTAL
Intervention: T40/A5
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: T40/A10
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: T80/A5
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: T80/A10
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: T40-T80/A5-A10
Number of subjects: 1814
Study: 24653515

Group type: EXPERIMENTAL
Intervention: Active TENS (transcutaneous electrical nerve stimulation) delivered via 2 electrodes on the venous cannulation site for 20 minutes before the procedure.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo TENS (no current)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 100
Study: 24653520

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (15 mg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: NaCl 0.9% solution (control group)
Number of subjects: 64
Study: 24653937

Group type: EXPERIMENTAL
Intervention: Levomilnacipran extended-release 40-120mg/day
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 24654876

Group type: EXPERIMENTAL
Intervention: Subthreshold pacing output for VVI pacing after ≥2 documented PITs
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Subthreshold pacing output for VVI pacing
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 550
Study: 24655096

Group type: EXPERIMENTAL
Intervention: Chronic unlimited recording electrocorticography-guided resective epilepsy surgery
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Chronic unlimited recording electrocorticography (CURE)
Number of subjects: 5

Group type: COMPARATOR
Intervention: RNS System (Responsive Neurostimulation System)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Resective surgery
Number of subjects: 5
Study: 24655157

Group type: EXPERIMENTAL
Intervention: Multimodal intervention strategy to improve processes of end-of-life care
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Interventions that support staff's ability to convey compassion and communicate information
Number of subjects: 78
Study: 24655689

Group type: EXPERIMENTAL
Intervention: SonR CRT optimization
Number of subjects: 876

Group type: COMPARATOR
Intervention: Control arm (echocardiographic optimization)
Number of subjects: 876
Study: 24655691

Group type: EXPERIMENTAL
Intervention: ORSIRO sirolimus-eluting stent with circumferential biodegradable coating
Number of subjects: 3540

Group type: EXPERIMENTAL
Intervention: SYNERGY everolimus-eluting stent with abluminal biodegradable coating
Number of subjects: 3540

Group type: COMPARATOR
Intervention: RESOLUTE INTEGRITY zotarolimus-eluting stent with durable coating
Number of subjects: 3540
Study: 24655693

Group type: EXPERIMENTAL
Intervention: 6-week clopidogrel therapy
Number of subjects: 600

Group type: COMPARATOR
Intervention: 6-month clopidogrel therapy
Number of subjects: 600
Study: 24655871

Group type: EXPERIMENTAL
Intervention: Sliding scale insulin to lower blood glucose levels (n = 145)
Number of subjects: 243

Group type: COMPARATOR
Intervention: No insulin (n = 98)
Number of subjects: 243
Study: 24656118

Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia with adenosine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cold pressor test
Number of subjects: 14
Study: 24656509

Group type: EXPERIMENTAL
Intervention: Protein-enriched low glycemic index diet with omega-3 PUFA supplementation
Number of subjects: 30
Study: 24657065

Group type: EXPERIMENTAL
Intervention: Endovascular aortic aneurysm repair (EVAR) using the Endurant endograft
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (patients aged <80 years)
Number of subjects: 290
Study: 24657127

Group type: EXPERIMENTAL
Intervention: Diet group
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1250
Study: 24657227

Group type: EXPERIMENTAL
Intervention: Survey on knowledge of CMS reimbursement rates
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Survey on impact of cost beliefs on ordering behavior
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Estimation of costs accuracy
Number of subjects: 97
Study: 24657695

Group type: EXPERIMENTAL
Intervention: CoreValve transcatheter heart valve (THV)
Number of subjects: 506
Study: 24657719

Group type: EXPERIMENTAL
Intervention: OAcPec-rEPA
Number of subjects: 25
Study: 24657993

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: pPCI
Number of subjects: 1492

Group type: COMPARATOR
Intervention: No reperfusion
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Prehospital fibrinolysis
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Fibrinolysis (beyond 90 minutes of call)
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Fibrinolysis (early population)
Number of subjects: 1492
Study: 24658821

Group type: EXPERIMENTAL
Intervention: pan-KIR2D blockade with IPH2101
Number of subjects: 0
Study: 24659579

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Untreated KS
Number of subjects: 70

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: KS males
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: KS patients
Number of subjects: 70
Study: 24659631

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study: 24660224

Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 409

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 409
Study: 24661373

Group type: EXPERIMENTAL
Intervention: VEGFR TKI patients (sunitinib or sorafenib)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Patient controls (mRCC not receiving systemic treatment)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study: 24661577

Group type: EXPERIMENTAL
Intervention: Rehabilitation program (3 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls (6 individuals)
Number of subjects: 48
Study: 24661633

Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cell transplantation (UC-MSCT)
Number of subjects: 40
Study: 24661732

Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 89

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 89
Study: 24661748

Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Variable-cost model
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Fixed-cost model
Number of subjects: 2500
Study: 24661784

Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor concentrate (C1-INH) at 20 IU/kg
Number of subjects: 57
Study: 24661824

Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hybrid Iterative Reconstruction (IR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Knowledge-based Iterative Model Reconstruction (IMR)
Number of subjects: 21
Study: 24661823

Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CTA) findings
Number of subjects: 3015

Group type: EXPERIMENTAL
Intervention: Follow-up coronary CTA at 2 years
Number of subjects: 3015

Group type: EXPERIMENTAL
Intervention: Blood pressure, serum lipid, and C-reactive protein levels
Number of subjects: 3015
Study: 24662399

Group type: EXPERIMENTAL
Intervention: Self-expandable transcatheter aortic valve (TAV)
Number of subjects: 55
Study: 24662448

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 102
Study: 24662454

Group type: EXPERIMENTAL
Intervention: Cetuximab plus cisplatin and vinorelbine (chemotherapy)
Number of subjects: 971
Study: 24664095

Group type: EXPERIMENTAL
Intervention: ICD
Number of subjects: 166

Group type: COMPARATOR
Intervention: PM
Number of subjects: 166
Study: 24664277

Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker
Number of subjects: 33
Study: 24664935

Group type: EXPERIMENTAL
Intervention: TNFα antagonist therapy
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Achilles enthesis hypervascularization by power Doppler
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Number of work days missed
Number of subjects: 708